Do men with mCRPC need to stay on ADT along with their abiraterone acetate?

On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). … READ MORE …

The future potential treatment of high-risk, progressive, nmHSPC

One of the clinical questions that is now beginning to be asked really seriously is this one: “Just how aggressively should we treat a man with high-risk progressive prostate cancer after first-line therapy?” … READ MORE …

The importance of 3 weeks … before starting docetaxel along with ADT

A new study in BJU International has shown the importance of waiting at least 3 weeks after initiation of androgen deprivation therapy (ADT) until initiation of docetaxel chemotherapy in the treatment of men with newly diagnosed, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Alzheimer’s, dementia, and androgen deprivation therapy (again)

A new study has concluded that added risk for Alzheimer’s disease and dementia among Medicare patients with prostate cancer who were treated with androgen deprivation therapy (ADT) was minimal in men treated between 2001 and 2014. … READ MORE …

ADT and cardiovascular side effects — redux

A few days ago we commented briefly on a paper by Haque et al. on the risk for cardiovascular complications and side effects of ADT in men initially diagnosed with localized prostate cancer and supposedly managed, initially, on active surveillance. … READ MORE …

ADT and risk for cardiovascular complications of therapy

Not so long ago, we addressed the question of whether first-line androgen deprivation therapy (ADT) was really an appropriate form of care for any man with localized prostate cancer. … READ MORE …

The TOAD trial: follow-up data on quality of life

Some 15 months ago, we reported the initial, primary results of the TOAD trial, which showed an overall survival benefit for immediate as opposed to delayed initiation of androgen deprivation therapy (ADT) in non-metastatic patients considered to be inappropriate for curative therapy. … READ MORE …